Keros Therapeutics Inc —— 资产负债表 (NASDAQ:KROS) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 269.44 M255.25 M306.78 M370.02 M615.89 M338.02 M 负债总额 7.72 M12.08 M29.36 M37.81 M44.33 M34.89 M 权益总额 261.72 M243.17 M277.42 M332.21 M571.55 M303.13 M 负债及股东权益总额 269.44 M255.25 M306.78 M370.02 M615.89 M338.02 M 总债务 —————— 净债务 ——————

新闻

Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?

KROS: Is the Discount Book Value a Value Trap?

KROS Stock: What to Know About Rinvatercept in DMD

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?

Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates

KerosQ1每股收益及营收逊于预期

Keros earnings missed by $0.16, revenue fell short of estimates

Keros Therapeutics任命前Lyell首席财务官加入董事会

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?

Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?